Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to the drug makers, writing in bold that the agency "reminds compounders of the legal restrictions on making copies of FDA-approved drugs."

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, Mounjaro and Zepbound, after the FDA declares the tirzepatide shortage resolved.

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and Zepbound has filed a lawsuit against the Food and Drug Administration

A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.

A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug Administration over the agency’s decision to remove Lilly’s medications from its shortage list.

A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's tirzepatide from an official shortages list.

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) weight loss drug tirzepatide. Read more here.